According to the Third Joint Task Force European guidelines and Hungarian national recommendations administration of platelet aggregation inhibitors, beta-blockers, ACE-inhibitors and statins is essential in patients with known cardiovascular disease for the prevention of new events. Statins became the drugs of first choice for the prevention because of their favourable effects in the reduction of cardiovascular and total mortality, and in the regression or slowing the progression of atherosclerotic process. A new agent in the class of statins, rosuvastatin is a synthetic compound, selectively taken up by hepatic cells, and due to its methylsulfonamid group inhibits to a greater extend the hydroxy-methyl-glutaryl-coenzyme-A reductase enzyme. Administration of daily 10-40 mg rosuvastatin has been shown to reduce the LDL-cholesterol level by 52-63%, and increase the HDL-cholesterol level up to 14%. These effects are greater than that of other currently available statins. Rosuvastatin has beneficial effects not only in hypercholesterolaemia, but in mixed hyperlipidaemia, hypertriglyceridaemia and lipid abnormalities in diabetes mellitus as well. This compound is well tolerated, has a good safety profile, due to its pharmacological properties can be applied in combination with other lipid lowering drugs. Its effects in monotherapy and the combination possibilities offer the physicians a new drug, which could help to achieve target lipid levels to a greater extend.
|Translated title of the contribution||A new lipid lowering drug in the horizont, the rosuvastatin|
|Number of pages||8|
|Publication status||Published - Dec 1 2005|
ASJC Scopus subject areas